Testing effectiveness (Phase 2)Ended earlyNCT05207722
What this trial is testing
CYNK-101 in Combination with Trastuzumab and Pembrolizumab in Patients with Locally Advanced Unresectable or Metastatic HER2-Positive Gastric or Gastroesophageal Junction (G/GEJ) Adenocarcinoma
Who this might be right for
Metastatic HER2 Positive Gastroesophageal Junction Cancer
Celularity Incorporated 1